Objective: The aim of this study was to determine whether intraoperative cytological evaluation of squash preparations is of benefit for differentiating high-grade from low-grade astrocytomas. Methods: Squash preparations of 42 astrocytomas were classified histologically according to the World Health Organization (WHO) 2007 classification system as grade II (n = 12), grade III (n = 11), and grade IV (n = 19) and were divided into 2 groups, namely a low-grade group (grade II) and a high-grade group (grades III and IV). The focus was on morphological cell and vessel characteristics, namely nuclear atypia, chromatin pattern, nuclear enlargement, variation in nuclear size, the presence of nucleoli, mitosis, tumor necrosis, cell density, multibranched vessels, and vascular dilatation, and these characteristics were compared between the low- and high-grade groups. Results: Nuclear atypia, the presence of coarse chromatin, variations in nuclear size, and cell density ≥200 per high-power field were significantly more prevalent in high- than in low-grade astrocytomas (p = 0.0407, p < 0.01, p < 0.01, and p < 0.01, respectively). Vessels with > 3 branches and a mean vessel diameter ≥20 μm were more prevalent in high- than in low-grade astrocytomas (p < 0.01). Conclusion: Squash preparation cytology provides added benefit for the intraoperative identification of high-grade astrocytoma.

Keywords:
Squash preparation, High-grade astrocytoma, Microvascular proliferation, Intraoperative diagnosis, Multibranched vessels
1.
Nakazato Y: Tumors of the Nervous System. Contemporary Pathology System 23 C. Tokyo, Nakayama Co, 1993, pp 141–177.
2.
Louis DN, Ohgaki H, Wiestetler OD (eds): WHO Classification of Tumors of the Central Nervous System, ed 4 revised. Lyon, IARC Press, 2016.
3.
Daumas-Duport C, Sheithauer, B, O’Fallon J, Kelly P: Grading of astrocytomas. A simple and reproducible method. Cancer 1988; 62: 2152–2165.
4.
Westphal M, Hilt DC, Bortey E: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003; 5: 79–88.
5.
Mehdorn HM, Schwartz F, Dawirs S: High-field iMRI in glioblastoma surgery: improvement of resection radicality and survival for the patient? Acta Neurochir Suppl 2011; 109: 103–106.
6.
Yamazaki H, Yokoo H, Hirato J, Nakazato Y: Imprint cytology of the astrocytic tumors (in Japanese with English abstract). J Jpn Soc Clin Cytol 2003; 42: 405–411.
7.
Inagawa H, Ishizawa K, Hirose T: Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma. Acta Cytol 2007; 51: 900–906.
8.
Iqubal M, Shah A, Wani MA, Kirmani A, Ramzan A: Cytopathology of central nervous system. Part I. Utility of crush smear cytology in intraoperative diagnosis of central nervous system lesions. Acta Cytol 2006; 50: 608–616.
9.
Folkerth RD: Smears and frozen sections in the intraoperative diagnosis of central nervous system lesions. Neurosurg Clin N Am 1994; 5: 1–18.
10.
Brommeland T, Lindal S, Straume B, Dahl IL, Hennig R: Does imprint cytology of brain tumours improve intraoperative diagnoses? Acta Neurol Scand 2003; 108: 53–156.
11.
Goel D, Sundaram C, Paul TR: Intraoperative cytology (squash smear) in neurosurgical practice – pitfalls in diagnosis experience based on 3057 samples from a single institution. Cytopathology 2007; 18: 300–308.
12.
Sato S, Sato Y, Marutsuka K, Takeshima H, Asada Y: Characteristics of tumour vessels in cytological squash smears of astrocytic tumours. Cytopathology 2011; 22: 313–317.
13.
Louis DN, Ohgaki H, Wiestetler OD (eds): WHO Classification of Tumors of the Central Nervous System, ed 4. Lyon, IARC Press, 2007.
14.
JSCC Atlas and Guidelines for Cytopathological Diagnosis, ed 3 (in Japanese). Tokyo, Kanehara Shupan Co, 2015, pp 149–151.
15.
Kanda Y: Investigation of the freely-available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 2013; 48: 452–458.
16.
Chaudhry IH, O’Donovan DG, Brenchley PE, Reid H, Roberts IS: Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001; 39: 409–415.
17.
Zhou YH, Tan F, Hess KR, Yung WK: The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 2003; 9: 3369–3375.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.